

They conclude that, even though making changes in hospital formularies may help contain the spread of some resistant pathogens, close surveillance is needed to detect the emergence of other resistant organisms.

FROM: Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant *Staphylococcus aureus* and ceftazidime-resistant *Klebsiella pneumoniae* following changes in a hospital antibiotic formulary. *Clin Infect Dis* 1999;28:1062-1066.

## Tunneled Femoral Catheters and Risk of Infection

Timsit and colleagues from St Joseph Hospital, Paris, France, recently report on a study that evaluated the effect of catheter tunneling on femoral catheter-related infection in critically ill patients.

In a randomized, controlled trial, the study population included 345 patients requiring a femoral venous catheter for more than 48 hours in three ICUs at academic hospitals in Paris, France.

Of 345 randomly assigned patients, 336 were evaluable. Probable systemic catheter-related sepsis occurred in 15 of 168 patients who received a nontunneled femoral catheter (controls) and in 5 of 168 patients who received a tunneled femoral catheter. Time to occurrence of catheter-related bloodstream infection was not significantly modified; three events occurred in the control group, and one event occurred in the tunneled-catheter group. After stratification by treatment center and adjustment for variables that were prognostic (use of broad-spectrum antimicrobial agents at catheter insertion) or imbalanced between both groups (mechanical ventilation at insertion), tunneled catheterization reduced the proportion of patients who developed systemic catheter-related sepsis ( $P=0.005$ ).

The authors concluded that the incidence of femoral catheter-related infections in critically ill patients can be reduced by using subcutaneous tunneling.

FROM: Timsit JF, Bruneel F, Cheval C, Mamzer MF, Garrouste-Orgeas M, Wolff M, et al. Use of tunneled femoral catheters to prevent catheter-related infection: a randomized, controlled trial. *Ann Intern Med* 1999;130:729-735.

## HCV Infection From Contaminated Anti-D Immune Globulin

In February 1994, batches of anti-D immune globulin used in Ireland during 1977 and 1978 to prevent Rh isoimmunization were found to be contaminated with hepatitis C virus (HCV) from a single infected donor. In March 1994, a national screening program was initiated for all women who had received anti-D immune globulin between 1970 and 1994. Of the 62,667 women who had been screened when this study began, 704 (1.1%) had evidence of past or current HCV infection, and 390 (55%) of those 704 had pos-

itive tests for serum HCV RNA on reverse-transcription polymerase chain reaction analysis. All 390 were offered a referral for clinical assessment and therapy. Researchers evaluated 376 (96%) of these 390 women.

A total of 304 women (81%) reported symptoms, most commonly fatigue (248 [66%]). Serum alanine aminotransferase concentrations were slightly elevated (40-99  $\mu$ /L) in 176 (47%) of 371 women, and the concentrations were 100  $\mu$ /L or higher in 31 (8%). Liver biopsies showed inflammation in 356 (98%) of 363 women; in most cases, the inflammation was slight (41%) or moderate (52%). Although the biopsy samples from 186 (51%) of the 363 women showed evidence of fibrosis, only 7 women (2%) had probable or definite cirrhosis. Two of the seven reported excessive alcohol consumption.

The researchers concluded that most of the women with HCV infection 17 years after receiving HCV-contaminated anti-D immune globulin had evidence of slight or moderate hepatic inflammation on liver biopsy, approximately one half had fibrosis, and 2% had probable or definite cirrhosis.

FROM: Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. *N Engl J Med* 1999;340:1228-1233.

## Reporting of Diseases by Healthcare Professionals and Laboratories

Surveillance is a key component of the core public-health function of health assessment. Systematic reporting by healthcare professionals and laboratories, which may vary by state law, statute, or regulation, continues to provide essential data for assessing public health. Researchers from the CDC recently described the state and territorial reporting requirements for diseases and conditions recommended for national public-health surveillance. Information was obtained during May and August 1997, and the state and territorial epidemiologists from all 50 states, in addition to New York City, Puerto Rico, and Guam, completed questionnaires indicating which diseases and conditions were reportable by healthcare professionals and laboratories in their jurisdictions. The overall response rate for the survey was 100% for US states and 90% overall, including the territories.

Of the 58 diseases and conditions recommended for national reporting, 35 (60%) were reportable in greater than 90% of the states and territories, 15 (26%) were reportable in 75% to 90%, and 8 (14%) were reportable in less than 75%. Nineteen of the infectious diseases were reportable in all of the states and territories that responded.

Required reporting varies substantially by state or territory. Healthcare professionals are integral to public-health efforts at the local, state, and national levels.

FROM: Roush S, Birkhead G, Koo D, Cobb A, Fleming D. Mandatory reporting of diseases and conditions by health care professionals and laboratories. *JAMA* 1999;282:164-170.



*The Society for Healthcare Epidemiology of America*

## 1999 SHEA/CDC Training Course in Hospital Epidemiology

### **Program**

The program will be held May 1-4, 1999 at the Wyndham Franklin Plaza Hotel, Philadelphia, Pennsylvania. Timothy W. Lane, M.D., Gina Pugliese, R.N., and Julie Gerberding, M.D. will chair the program.

### **Purpose**

This program, developed by the Society for Healthcare Epidemiology of America (SHEA), and the Centers for Disease Control and Prevention (CDC), is intended for infectious disease fellows and new hospital epidemiologists. It emphasizes hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These work sessions are supplemented with lectures and seminars covering fundamental aspects of hospital epidemiology and surveillance, epidemic investigation, transmission and control of nosocomial infections, disinfection and sterilization, employee health, isolation systems, regulatory compliance, and quality improvement.

### **Who Should Attend**

You should attend if you are a hospital epidemiologist or an infection control practitioner or if you are looking for a course that will provide you the most current information concerning infection control practices and epidemiological methods in health care. This fundamental program will provide you with the opportunities to find solutions to real situations that will occur in the hospital setting. Intensive problem solving sessions are supplemented with lectures and seminars presented by leading authorities.

### **Scholarships**

Scholarships in the amount of \$1,000 will be awarded to infectious disease fellows for the program to defray the special course fee for fellows of \$350 and expenses incurred in attending the training program.

Interested fellows must submit a letter of no more than one page describing why they would like to have additional training in hospital epidemiology. A letter from the fellow's program director outlining the applicant's qualifications and suitability for the course also is required. The deadline for receipt of scholarship applications for the course is March 26, 1998.

The SHEA Educational Activities Committee will select the scholarship recipients based on review of these letters. Winners will be notified in September.

### **Nominations**

Please send scholarship applications to:

Timothy W. Lane, M.D.

c/o The Society for Healthcare Epidemiology of America

19 Mantua Road

Mt. Royal, NJ 08061

### **Fees**

Individual Registrants \$495

Fellows in Infectious Disease \$350

### **Credits**

The Society for Healthcare Epidemiology of America (SHEA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

SHEA designates this continuing education activity for up to 23 hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

The SHEA/CDC Training Course is AACN (American Association of Critical Care Nurses) approved for 28.5 hours.

### **General Course Information**

Information regarding the schedule, hotel and travel accommodations, discount airfare, and course fees are available from SHEA (609) 423-7222 x350. Note that application for a scholarship does not constitute enrollment in the program. This must be done separately.

Scholarship Awards provided in part by an educational grant from Pfizer Pharmaceuticals.



Labs • NHO • Pratt • Roerig • Specialty

U.S. Pharmaceuticals Group